Literature DB >> 20451217

Tryptophan-hydroxylase 2 haplotype association with borderline personality disorder and aggression in a sample of patients with personality disorders and healthy controls.

M Mercedes Perez-Rodriguez1, Shauna Weinstein, Antonia S New, Laura Bevilacqua, Qiaoping Yuan, Zhifeng Zhou, Colin Hodgkinson, Marianne Goodman, Harold W Koenigsberg, David Goldman, Larry J Siever.   

Abstract

BACKGROUND: There is a decreased serotonergic function in impulsive aggression and borderline personality disorder (BPD), and genetic association studies suggest a role of serotonergic genes in impulsive aggression and BPD. Only one study has analyzed the association between the tryptophan-hydroxylase 2 (TPH2) gene and BPD. A TPH2 "risk" haplotype has been described that is associated with anxiety, depression and suicidal behavior.
METHODS: We assessed the relationship between the previously identified "risk" haplotype at the TPH2 locus and BPD diagnosis, impulsive aggression, affective lability, and suicidal/parasuicidal behaviors, in a well-characterized clinical sample of 103 healthy controls (HCs) and 251 patients with personality disorders (109 with BPD). A logistic regression including measures of depression, affective lability and aggression scores in predicting "risk" haplotype was conducted.
RESULTS: The prevalence of the "risk" haplotype was significantly higher in patients with BPD compared to HCs. Those with the "risk" haplotype have higher aggression and affect lability scores and more suicidal/parasuicidal behaviors than those without it. In the logistic regression model, affect lability was the only significant predictor and it correctly classified 83.1% of the subjects as "risk" or "non-risk" haplotype carriers.
CONCLUSIONS: We found an association between the previously described TPH2 "risk" haplotype and BPD diagnosis, affective lability, suicidal/parasuicidal behavior, and aggression scores.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20451217      PMCID: PMC2955771          DOI: 10.1016/j.jpsychires.2010.03.014

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  74 in total

1.  Analysis of the novel TPH2 gene in bipolar disorder and suicidality.

Authors:  V De Luca; D J Mueller; S Tharmalingam; N King; J L Kennedy
Journal:  Mol Psychiatry       Date:  2004-10       Impact factor: 15.992

2.  A preliminary trial of fluoxetine in refractory borderline patients.

Authors:  J R Cornelius; P H Soloff; J M Perel; R F Ulrich
Journal:  J Clin Psychopharmacol       Date:  1991-04       Impact factor: 3.153

Review 3.  Recent advances in the biological study of personality disorders.

Authors:  Antonia S New; Marianne Goodman; Joseph Triebwasser; Larry J Siever
Journal:  Psychiatr Clin North Am       Date:  2008-09

4.  Blunted prolactin responses to d-fenfluramine in sociopathy. Evidence for subsensitivity of central serotonergic function.

Authors:  V O'Keane; E Moloney; H O'Neill; A O'Connor; C Smith; T G Dinan
Journal:  Br J Psychiatry       Date:  1992-05       Impact factor: 9.319

5.  Tryptophan hydroxylase genotype is associated with impulsive-aggression measures: a preliminary study.

Authors:  A S New; J Gelernter; Y Yovell; R L Trestman; D A Nielsen; J Silverman; V Mitropoulou; L J Siever
Journal:  Am J Med Genet       Date:  1998-02-07

6.  SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder.

Authors:  Thomas Rinne; Wim van den Brink; Luuk Wouters; Richard van Dyck
Journal:  Am J Psychiatry       Date:  2002-12       Impact factor: 18.112

7.  [A twin study of personality disorder heritability].

Authors:  Wen-yan Ji; Yong-hua Hu; Yue-qin Huang; Wei-hua Cao; Jun Lv; Ying Qin; Zeng-chang Pang; Shao-jie Wang; Li-ming Li
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2006-02

8.  Neurobiological correlates of diagnosis and underlying traits in patients with borderline personality disorder compared with normal controls.

Authors:  Joel Paris; Hallie Zweig-Frank; N M K Ng Ying Kin; George Schwartz; Howard Steiger; N P V Nair
Journal:  Psychiatry Res       Date:  2004-01-01       Impact factor: 3.222

9.  Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism.

Authors:  A Rousseva; C Henry; D van den Bulke; G Fournier; J-L Laplanche; M Leboyer; F Bellivier; J-M Aubry; P Baud; M Boucherie; C Buresi; F Ferrero; A Malafosse
Journal:  Pharmacogenomics J       Date:  2003       Impact factor: 3.550

10.  Abuse and neglect in childhood: relationship to personality disorder diagnoses.

Authors:  Linda M Bierer; Rachel Yehuda; James Schmeidler; Vivian Mitropoulou; Antonia S New; Jeremy M Silverman; Larry J Siever
Journal:  CNS Spectr       Date:  2003-10       Impact factor: 3.790

View more
  18 in total

Review 1.  Developmental pathways to borderline personality disorder.

Authors:  Andrew M Chanen; Michael Kaess
Journal:  Curr Psychiatry Rep       Date:  2012-02       Impact factor: 5.285

Review 2.  Sex differences modulating serotonergic polymorphisms implicated in the mechanistic pathways of risk for depression and related disorders.

Authors:  LeeAnn M Perry; Andrea N Goldstein-Piekarski; Leanne M Williams
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

3.  Genetic depletion of brain 5HT reveals a common molecular pathway mediating compulsivity and impulsivity.

Authors:  Mariana Angoa-Pérez; Michael J Kane; Denise I Briggs; Catherine E Sykes; Mrudang M Shah; Dina M Francescutti; David R Rosenberg; David M Thomas; Donald M Kuhn
Journal:  J Neurochem       Date:  2012-04-13       Impact factor: 5.372

Review 4.  Advances in tryptophan hydroxylase-2 gene expression regulation: new insights into serotonin-stress interaction and clinical implications.

Authors:  Guo-Lin Chen; Gregory M Miller
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-03       Impact factor: 3.568

Review 5.  Past, present, and future of genetic research in borderline personality disorder.

Authors:  Anahita Bassir Nia; Matthew C Eveleth; Jonathan M Gabbay; Yonis J Hassan; Bosi Zhang; M Mercedes Perez-Rodriguez
Journal:  Curr Opin Psychol       Date:  2017-09-12

6.  Examining the association of NRXN3 SNPs with borderline personality disorder phenotypes in heroin dependent cases and socio-economically disadvantaged controls.

Authors:  Vassilis N Panagopoulos; Timothy J Trull; Anne L Glowinski; Michael T Lynskey; Andrew C Heath; Arpana Agrawal; Anjali K Henders; Leanne Wallace; Alexandre A Todorov; Pamela A F Madden; Elizabeth Moore; Louisa Degenhardt; Nicholas G Martin; Grant W Montgomery; Elliot C Nelson
Journal:  Drug Alcohol Depend       Date:  2012-12-12       Impact factor: 4.492

7.  The effects of brain serotonin deficiency on behavioural disinhibition and anxiety-like behaviour following mild early life stress.

Authors:  Benjamin D Sachs; Ramona M Rodriguiz; William B Siesser; Alexander Kenan; Elizabeth L Royer; Jacob P R Jacobsen; William C Wetsel; Marc G Caron
Journal:  Int J Neuropsychopharmacol       Date:  2013-05-14       Impact factor: 5.176

Review 8.  The role of the serotonergic system at the interface of aggression and suicide.

Authors:  M Bortolato; N Pivac; D Muck Seler; M Nikolac Perkovic; M Pessia; G Di Giovanni
Journal:  Neuroscience       Date:  2013-01-16       Impact factor: 3.590

Review 9.  Monoamine-sensitive developmental periods impacting adult emotional and cognitive behaviors.

Authors:  Deepika Suri; Cátia M Teixeira; Martha K Caffrey Cagliostro; Darshini Mahadevia; Mark S Ansorge
Journal:  Neuropsychopharmacology       Date:  2014-09-02       Impact factor: 7.853

10.  Associations between prefrontal γ-aminobutyric acid concentration and the tryptophan hydroxylase isoform 2 gene, a panic disorder risk allele in women.

Authors:  Nora Preuss; Basira Salehi; Jan Willem van der Veen; Jun Shen; Wayne C Drevets; Colin Hodgkinson; David Goldman; Gregor Hasler
Journal:  Int J Neuropsychopharmacol       Date:  2013-04-03       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.